PMID- 20172326
OWN - NLM
STAT- MEDLINE
DCOM- 20100603
LR  - 20100222
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 42
IP  - 1
DP  - 2010 Jan-Feb
TI  - Evaluation of HLA Matchmaker compatibility as predictor of graft survival and 
      presence of Anti-HLA antibodies.
PG  - 266-9
LID - 10.1016/j.transproceed.2009.12.047 [doi]
AB  - BACKGROUND: HLA Matchmaker is a computer algorithm developed to evaluate 
      donor/receptor compatibility comparing sequences of polymorphic aminoacids 
      (eplets) present in human leukocyte antigen (HLA) molecules. The aim of this 
      study was to evaluate the predictive value of HLA Matchmaker for patient and 
      graft survival, graft survival free of rejection, and the presence of anti HLA 
      antibodies. METHODS: Using this program, 62 of 173 kidney transplant patients, 
      were retrospectively analyzed. HLA-I loci eplet mismatch value (EMM) was 
      determined and correlated with graft survival, graft survival free of rejection, 
      and the presence of anti HLA-I antibodies. EMM was compared with the traditional 
      HLA antigen mismatch value (MM) in terms of the presence of anti HLA-I 
      antibodies. RESULTS: Graft survival and graft survival free of rejection showed 
      no statistical differences (P-value .975 and .365, respectively) while comparing 
      patients with less or more than 10 HLA-I EMM. Patients with > or =6 HLA-B EMM had 
      an odds ratio (OR) of 5.6 (95% confidence interval [CI], 0.47-66.45) of 
      presenting anti HLA-I antibodies, with a sensitivity of 80% and specificity of 
      58.3%. For > or =2 HLA-B MM, the OR was 2.58 (95% CI, 0.46-14.5), with a 
      sensitivity of 40% and specificity of 75%. CONCLUSION: Even though in our study 
      population compatibility by HLA Matchmaker did not correlate with graft survival 
      or rejection-free graft survival, it showed a better sensitivity than traditional 
      HLA antigen matching for the presence of anti HLA-I antibodies. HLA Matchmaker is 
      a promising tool in predicting the appearance of anti-HLA antibodies.
FAU - Silva, E
AU  - Silva E
AD  - Centro Clinico epidemiologico, Hospital Clinico de la Universidad de Chile.
FAU - Alba, A
AU  - Alba A
FAU - Castro, A
AU  - Castro A
FAU - Carrascal, M
AU  - Carrascal M
FAU - Buckel, E
AU  - Buckel E
FAU - Aguilo, J
AU  - Aguilo J
FAU - Herzog, C
AU  - Herzog C
FAU - Calabran, L
AU  - Calabran L
FAU - Morales, J
AU  - Morales J
FAU - Fierro, J A
AU  - Fierro JA
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
RN  - 0 (HLA Antigens)
RN  - 0 (HLA-D Antigens)
RN  - 0 (Histocompatibility Antigens Class I)
SB  - IM
MH  - Adult
MH  - Cadaver
MH  - Female
MH  - Graft Rejection/epidemiology/immunology
MH  - Graft Survival/*immunology
MH  - HLA Antigens/*immunology
MH  - HLA-D Antigens/immunology
MH  - Histocompatibility Antigens Class I/immunology
MH  - Histocompatibility Testing
MH  - Humans
MH  - Kidney Diseases/classification/surgery
MH  - Kidney Transplantation/immunology/*physiology
MH  - Living Donors
MH  - Male
MH  - Middle Aged
MH  - Polymerase Chain Reaction
MH  - Retrospective Studies
MH  - Tissue Donors
EDAT- 2010/02/23 06:00
MHDA- 2010/06/04 06:00
CRDT- 2010/02/23 06:00
PHST- 2010/02/23 06:00 [entrez]
PHST- 2010/02/23 06:00 [pubmed]
PHST- 2010/06/04 06:00 [medline]
AID - S0041-1345(09)01803-X [pii]
AID - 10.1016/j.transproceed.2009.12.047 [doi]
PST - ppublish
SO  - Transplant Proc. 2010 Jan-Feb;42(1):266-9. doi: 
      10.1016/j.transproceed.2009.12.047.